WO2006033372A1 - 美白剤 - Google Patents
美白剤 Download PDFInfo
- Publication number
- WO2006033372A1 WO2006033372A1 PCT/JP2005/017434 JP2005017434W WO2006033372A1 WO 2006033372 A1 WO2006033372 A1 WO 2006033372A1 JP 2005017434 W JP2005017434 W JP 2005017434W WO 2006033372 A1 WO2006033372 A1 WO 2006033372A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- elephantopus
- phase
- whitening agent
- whitening
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
Definitions
- the present invention relates to a whitening agent. More specifically, the present invention is effective in preventing and improving pigmentation, blemishes, freckles, liver spots, etc. after sunburn, and is excellent in skin whitening.
- the present invention relates to a whitening agent having an effect.
- melanin pigments are usually formed due to abnormalities in hormones or the stimulation of ultraviolet rays from sunlight. It is thought to deposit.
- This melanin pigment which causes skin coloring, is produced in melanin granules (melanosomes) in the melanocytes (melanocytes) between the epidermis and dermis, and the generated melanin is transferred to neighboring cells by permeation. Spread.
- the biochemical reaction in this melanocyte is estimated as follows.
- tyrosine an essential amino acid
- tyrosine an essential amino acid
- an object of the present invention is to provide a new plant-derived whitening agent in response to such a conventional situation.
- a whitening agent comprising a solvent extract of the family Comos itae, Elephantbus morris hay. B. and K. (Elephantopus mol 1 is H. B. & K.).
- a solvent extract of the Compositaeae plant Elephant pus morrischai (Elephantopus mol 1 is HB & K.) and a skin external preparation base.
- An external preparation composition for skin is provided.
- the whitening agent of the present invention has an excellent whitening effect, and has excellent effects on lightening and whitening of pigment deposits, stains, freckles, and liver spots after sunburn.
- the extract of Elephantopus mollis HB & K. used in the present invention is The above-mentioned plant leaves, stems, flowers, seeds or whole plants are soaked or heated to reflux with an extraction solvent at a temperature of 10 to 90 ° C, preferably at room temperature, and then filtered and concentrated.
- the extraction solvent used in the present invention may be any solvent that is usually used for extraction, and in particular, alcohols such as methanol, ethanol, 1,3-butylene glycol, hydrous alcohols, acetone, and ethyl acetate.
- organic solvents such as esters can be used alone or in combination, alcohols such as methanol, ethanol and 1,3-butylene glycol are particularly preferred.
- extraction solvent containing a large amount of water extraction of the active component is suppressed, which is not preferable.
- the blending amount of the whitening agent containing the extract of Elephantopus mollis HB & K. in the skin external preparation composition of the present invention is not particularly limited, but is 0.000 as a dry product in the total amount of the external preparation composition. ⁇ 20.0 mass%, preferably 0.00 1 ⁇ : L 0.0 mass%. If the amount is less than 0, 0 0 5% by mass, the effects of the present invention may not be sufficiently exhibited, and if it exceeds 20.0% by mass, formulation may be difficult. It should be noted that even when blended in an amount of 10.0 mass% or more, it is difficult to recognize a significant improvement in the effect.
- the skin external preparation composition of the present invention in addition to the extract of Elephantopus mollis HB & K., the skin external preparation composition of the present invention, other than the extract of the above-mentioned Elephantopus mollis HB & K.
- Antioxidants, oil components, UV absorbers, surfactants, thickeners, alcohols, powder components, colorants, aqueous components, water, various skin nutrients, etc. should be combined as necessary. Can do.
- metal sequestering agents such as disodium edetoxalate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium methacrylate, darconic acid, caffeine, tannin, verapamil, tranexamic acid And its derivatives, licorice extract, Labrizine, hot water extract of fire thorn fruit, various herbal medicines, tocopherol acetate, drugs such as glycyrrhizic acid and its derivatives or its salts, Bimin C, magnesium ascorbyl phosphate, glucose ascorbate
- Other whitening agents such as coside, arbutin, and kojic acid, and sugars such as glucose, fructose, mannose, sucrose, and trehalose can be appropriately blended.
- the skin external preparation composition of the present invention may be any ophthalmic ointment, cream, milky lotion, mouth-skin, pack, bath preparation, etc., as long as it is used in conventional skin external preparation compositions, and the dosage form is not particularly limited. Absent.
- Elephantopus mol 1 is HB & K. Leaves 5. Use O g, soak in 50 mL of ethanol at room temperature for 7 days, filter, and evaporate the solvent to obtain 2 25 mg of ethanol extract. It was.
- the 1,3-butylene glycol extract and ethanol extract obtained above were measured and evaluated for the melanin production inhibitory effect.
- Mouse B 16 melanoma cells were used.
- a medium containing eagle serum (FBS, 10%) and melanocyte stimulating hormone (OiMSH, 10 ng / ml) in Eagle ME M was used as a test medium.
- the cells were grown in a CO 2 incubator using Eagle's MEM medium containing F B S (10%) in 75 cm 2 flask.
- the cells were detached with trypsin solution, added with Eagle M EM medium containing F B S (10%), and centrifuged at 1,100 rpm to collect the cells.
- the test medium was replaced and the test sample was added at 2 concentrations (2.5 and 5 pPm as solid content), and the culture was continued for 3 days.
- the amount of melanin per cell was measured by the following method. .
- Table I shows the results using the 1,3-butylene glycol extract
- Table II shows the results using the ethanol extract.
- Propylene glycol, Elephantopus mollis H. B. & K. Methanol extract and caustic liquid are added to ion-exchanged water, dissolved, and heated to 70 ° C (aqueous phase). Mix other ingredients, heat and melt and maintain at 70 ° C (oil phase). Gradually add the oil phase to the water phase, and after all of it has been added, keep the temperature for a while to react. Then, uniformly emulsify with a homomixer and cool to 30 ° C while stirring well.
- Vaseline 1 5. 0
- Carpoxyvinyl polymer 0. 0 5
- phase A Dissolve force loxyvinyl polymer in a small amount of ion-exchanged water (phase A).
- phase A Add polyethylene glycol 15500 and triethanolamine to the remaining ion-exchanged water, dissolve by heating and maintain at 70 ° C (aqueous phase). Mix other ingredients, heat and melt and keep at 70 ° C (oil phase).
- oil phase to the water phase, preliminarily emulsify, add phase A, homogenously emulsify with a homomixer, and cool to 30 ° C while stirring well after emulsification.
- Carboxyvinyl polymer 1.0 Caustic soda 0.1 5 L-arginine 0.1
- Example 10 Emulsification foundation (cream type)
- Titanium dioxide 1 0 3
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/662,284 US20080003189A1 (en) | 2004-09-24 | 2005-09-15 | Whitening Agent |
CN2005800319389A CN101027041B (zh) | 2004-09-24 | 2005-09-15 | 美白剂 |
EP05785798A EP1792599A4 (en) | 2004-09-24 | 2005-09-15 | BLEACH |
KR1020077005927A KR101251112B1 (ko) | 2004-09-24 | 2005-09-15 | 미백제 |
US12/585,271 US20100008879A1 (en) | 2004-09-24 | 2009-09-10 | Whitening agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-277298 | 2004-09-24 | ||
JP2004277298 | 2004-09-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/585,271 Continuation US20100008879A1 (en) | 2004-09-24 | 2009-09-10 | Whitening agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006033372A1 true WO2006033372A1 (ja) | 2006-03-30 |
Family
ID=36090129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017434 WO2006033372A1 (ja) | 2004-09-24 | 2005-09-15 | 美白剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20080003189A1 (ja) |
EP (1) | EP1792599A4 (ja) |
KR (1) | KR101251112B1 (ja) |
CN (1) | CN101027041B (ja) |
TW (1) | TWI372635B (ja) |
WO (1) | WO2006033372A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754121B2 (en) * | 2010-08-20 | 2014-06-17 | Academia Sinica | Use of deoxyelephantopin (DET) and analogues thereof for treatment of melanoma |
CN103585226B (zh) * | 2013-10-31 | 2015-09-02 | 山东省肿瘤防治研究院 | 一种毛莲菜提取物的制备方法及其应用 |
US20160069867A1 (en) | 2014-09-04 | 2016-03-10 | Shiseido Company, Ltd. | Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method |
TWI666444B (zh) * | 2014-03-05 | 2019-07-21 | 日商資生堂股份有限公司 | 以表皮絲胺酸消旋酶及/或d-絲胺酸量為指標之皮膚之障壁機能促進藥劑之篩選方法及皮膚障壁機能評價方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0987135A (ja) * | 1995-07-13 | 1997-03-31 | Shiseido Co Ltd | 皮膚外用剤 |
JP2001226369A (ja) * | 2000-02-10 | 2001-08-21 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | セスキテルペノイド化合物及びそれを含む医薬 |
JP2003306421A (ja) * | 2002-04-17 | 2003-10-28 | Pola Chem Ind Inc | メラノサイトのデンドライト伸長抑制剤及びそれを含有してなる皮膚外用剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US438636A (en) * | 1890-10-21 | Half to william henderson | ||
JP2000095663A (ja) * | 1998-09-24 | 2000-04-04 | Kose Corp | 植物抽出物を含有する外用剤 |
US6753363B1 (en) | 1999-07-16 | 2004-06-22 | Polyplastics Co., Ltd. | Polyacetal resin composition and process for production thereof |
EP1302113B1 (en) * | 2000-07-19 | 2010-09-08 | Unitika Ltd. | Physiologically functional foods and cosmetics containing sphingoglycolipids extracted from konjac for enhancing skin moisture retention and improving skin roughening |
JP2005002050A (ja) * | 2003-06-12 | 2005-01-06 | Shiseido Co Ltd | 美白剤及びこれを配合した皮膚外用剤 |
-
2005
- 2005-09-15 CN CN2005800319389A patent/CN101027041B/zh active Active
- 2005-09-15 WO PCT/JP2005/017434 patent/WO2006033372A1/ja active Application Filing
- 2005-09-15 US US11/662,284 patent/US20080003189A1/en not_active Abandoned
- 2005-09-15 KR KR1020077005927A patent/KR101251112B1/ko active IP Right Grant
- 2005-09-15 EP EP05785798A patent/EP1792599A4/en not_active Withdrawn
- 2005-09-21 TW TW094132576A patent/TWI372635B/zh active
-
2009
- 2009-09-10 US US12/585,271 patent/US20100008879A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0987135A (ja) * | 1995-07-13 | 1997-03-31 | Shiseido Co Ltd | 皮膚外用剤 |
JP2001226369A (ja) * | 2000-02-10 | 2001-08-21 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | セスキテルペノイド化合物及びそれを含む医薬 |
JP2003306421A (ja) * | 2002-04-17 | 2003-10-28 | Pola Chem Ind Inc | メラノサイトのデンドライト伸長抑制剤及びそれを含有してなる皮膚外用剤 |
Non-Patent Citations (5)
Title |
---|
CHEMISCHE BERICHTE JAHRG., vol. 109, no. 12, 1977, pages 3956 - 3957, XP002993392 * |
DATABASE CHEMICAL ABSTRACTS. [online] BOHLMANN F ET AL: "A new curcumene derivatives form Elephantopus mollis HBK.", XP002993392, Database accession no. (27656) * |
DATABASE CHEMICAL ABSTRACTS. [online] CAO HUI ET AL: "Molecular evidences on separation and combination of the General elephantpous L. and Pseudoelephantopus Rohr (compositae) in china.", XP002993393, Database accession no. (350756) * |
See also references of EP1792599A4 * |
vol. 7, no. 3, 2000, pages 181 - 190 * |
Also Published As
Publication number | Publication date |
---|---|
EP1792599A1 (en) | 2007-06-06 |
KR101251112B1 (ko) | 2013-04-04 |
KR20070057835A (ko) | 2007-06-07 |
CN101027041B (zh) | 2010-06-16 |
US20080003189A1 (en) | 2008-01-03 |
CN101027041A (zh) | 2007-08-29 |
TW200626182A (en) | 2006-08-01 |
EP1792599A4 (en) | 2012-07-11 |
US20100008879A1 (en) | 2010-01-14 |
TWI372635B (en) | 2012-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3481386B2 (ja) | 美白用皮膚外用剤 | |
JPH11246347A (ja) | 美白用皮膚外用剤 | |
WO2006033372A1 (ja) | 美白剤 | |
JPH0812560A (ja) | 皮膚外用剤 | |
JPH0812566A (ja) | チロシナーゼ活性阻害剤 | |
EP0919218B1 (en) | Dermatological preparations for whitening the skin | |
JPH0812561A (ja) | 美白用皮膚外用剤 | |
JPH08310939A (ja) | 美白用皮膚外用剤 | |
JP4764079B2 (ja) | 美白剤 | |
JP2008247841A (ja) | 美白剤およびメラニン生成抑制剤 | |
JP2000159626A (ja) | 皮膚外用剤 | |
JPH0930949A (ja) | 美白用皮膚外用剤 | |
JPH0812549A (ja) | 皮膚外用剤 | |
JP3527406B2 (ja) | 美白用皮膚外用剤 | |
EP0689831B1 (en) | Liniment for melanin inhibtors | |
JPH11246344A (ja) | 美白用皮膚外用剤 | |
JP2007126367A (ja) | 美白剤、美白方法および美白用皮膚外用剤の製造方法 | |
JPH10265363A (ja) | チロシナーゼ阻害剤 | |
JPH11246343A (ja) | 美白用皮膚外用剤 | |
JP3263246B2 (ja) | 皮膚外用剤 | |
JPH0812557A (ja) | 皮膚外用剤 | |
JPH11139952A (ja) | 美白用皮膚外用剤 | |
JPH0812550A (ja) | 皮膚外用剤 | |
JPH0930950A (ja) | 美白用皮膚外用剤 | |
JPH0812554A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11662284 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005785798 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077005927 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580031938.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005785798 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11662284 Country of ref document: US |